Browse News
Filter News
Found 2,297 articles
-
CytomX Therapeutics to Present at the 2023 Jefferies Healthcare Conference
6/1/2023
CytomX Therapeutics, Inc. announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Healthcare Conference on Thursday, June 8 at 4:00 p.m. ET.
-
Moderna to Present at Upcoming Conferences in June 2023
6/1/2023
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences.
-
Violet Therapeutics raises $10.6 million in seed funding led by the Dementia Discovery Fund (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and Mass General Brigham Ventures (MGBV)
5/31/2023
Violet Therapeutics, Inc., a therapeutics company utilizing novel proprietary platforms for the identification of cell-cell interaction mechanisms, announces the successful closing of a $10.6 million seed funding round.
-
Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
5/30/2023
Moderna, Inc. today announced that two abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6 in Chicago, IL.
-
$12+ Billion Influenza Vaccines Market to Grow at 7+% CAGR, Globally, by 2028 Lead by Quadrivalent Vaccines Segment with 88.36% Market Share in 2022 | The Insight Partners
5/30/2023
The Insight Partners published latest research study on "Influenza Vaccines Market Size, Share, Revenue, Growth Strategy, Industry Trends and Forecast to 2028
-
Synthetic Biology Market to Grow at 20% CAGR to be Worth $37.85 Billion, Globally, by 2028 - Exclusive Report by The Insight Partners
5/26/2023
The Insight Partners published latest research study on "Synthetic Biology Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Products (Enzymes, Chassis Organisms, Oligonucleotides, and Xeno-Nucleic Acids), Technology (Measurement & Modeling, Cloning & Sequencing
-
The Massachusetts-based company has claimed the year’s largest fundraise so far and secured a powerhouse R&D partner in Novo Nordisk to develop gene editing medicines.
-
ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth
5/24/2023
ElevateBio, LLC announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by Matrix Capital Management, and joined by a leading group of new and existing investors.
-
Harvard Professor and Entrepreneur Tim Springer Donates $210 Million to the Institute for Protein Innovation
5/24/2023
The Institute for Protein Innovation, a nonprofit research organization, announced a $210 million gift from Tim Springer, Ph.D., veteran entrepreneur and professor at Harvard Medical School and Boston Children’s Hospital, who founded IPI in 2017 with Andrew Kruse, Ph.D.
-
GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients
5/24/2023
GeoVax Labs, Inc. (Nasdaq: GOVX) announced today the presentation of updates on the development of its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 clinical trial, during the Vaccines Summit Boston 2023 and the Congress for the International Society for the Advancement of Cytometry (CYTO) 2023 meetings.
-
The Massachusetts-based startup’s goal is to develop RNA medicines that can treat diseases anywhere in the body using an “all-in-one” platform.
-
ReNAgade Therapeutics Launches with over $300 Million in Series A Financing To Unlock the Limitless Potential of RNA Medicine
5/23/2023
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines to correct disease, announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures.
-
ReCode–a New Contestant in the mRNA Race
5/22/2023
ReCode plans to use its SORT LNP genetic medicines delivery technology to treat CF and PCD patients who don’t respond to current treatments. -
Influenza Vaccines Market (Vaccine Type, Virus Type) - Reach $12.27Bn by 2028 at 7.4% CAGR with Quadrivalent Vaccine Segment Driving Growth During 2022–2028 | The Insight Partners
5/22/2023
The Insight Partners published latest research report on "Influenza Vaccines Market Size Report, Share, Trends, Growth, Demand & Forecast to 2028 - COVID-19 Impact and Global Analysis By Vaccine Type, Virus Type, Technology, Route of Administration, and Target Group”, the global market size is projected to reach USD 12,272.49 million by 2028 from USD 7,478.53 million in 2021
-
Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
5/19/2023
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement.
-
Alltrna Engineers tRNA Oligonucleotide with Improved Potency and Activity for In Vivo Readthrough of Premature Termination Codons
5/18/2023
Alltrna today announces the presentation of the first proof-of-concept data at multiple scientific forums this month.
-
Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction
5/17/2023
Sania Therapeutics launches today by unveiling its suite of proprietary patented platforms at the American Society of Gene & Cell Therapy (ASGCT) conference.
-
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
5/16/2023
Flagship Pioneering, the bioplatform innovation company, announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics.
-
Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
5/15/2023
Merck, known as MSD outside of the United States and Canada, announced that data for four approved medicines and two pipeline candidates in more than 25 types of cancer will be presented at the 2023 American Society of Clinical Oncology Annual Meeting in Chicago from June 2-6.
-
At 31.2% CAGR, Neoantigens Market Lead by Use of AI in Neoantigen Vaccine Development (2023-2028) | The Insight Partners
5/15/2023
The Insight Partners published latest research report on "Neoantigens Market Analysis Report, Size, Share, Trends, Growth & Demand Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment and Therapeutic Specialty”,